Bcr/abl fusion gene associated with reciprocal translocation t(9;22) occurs in 15-25% of adults with acute lymphoblastic leukemia (ALL) and in 3-5% of pediatric ALL. which is called Philadelphia chromosome-positive ALL (Ph-positive ALL). After intensive induction therapy, the rate of remission is similar in Ph-positive and Ph-negative patients, but Ph-positive patients have a significantly shorter duration of remission and survival in either case with minor bcr/abl (P190 subtype) or with major bcr/abl (P210 subtype). As of now, only allogeneic stem cell transplantation in first remission is curative for patients Correspondence:
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NHLs. These results, together with previous data we had obtained for the locus INK4a and p53 gene, are indicated in Table 1 . With regard to p73, Schultheis et al 7 have reported heterozygous deletion at D1Z2 region (which presumably contains p73 gene) in 6/74 (8.10%) patients with multiple myeloma. However, neither allelic losses nor rearrangement of p73 were found in any of the studied cell lines from lymphoid malignancies that lack expression of this gene. Interestingly, we detected loss of heterozygosity or microsatellite instability for the internal p73-Sty1 marker in 1/4 informative T cell NHLs (25%), and in 2/17 informative B cell NHLs (11.76%). The number of B-NHLs with p73 alterations increases to 6/17 (32.29%) when we also consider the microsatellites D1S468 and D1S243 (Figure 1a-c) , thus reinforcing the role for this gene in hematological malignancies. On the other hand, it has been proposed that myeloid neoplasias lacking p53 alterations might show a loss of heterozygosity at 1p35-1p36 (where p73 gene is located), 7 but this relationship is not clear in NHLs. Our results showed that only two of the six NHLs with alterations at p73, also have mutated p53. Conversely, only two of the six NHLs with mutated p53 also exhibit p73 alterations.
Deletions and rearrangements of 10q22-25 have been described in a fraction (5-10%) of NHLs. Recently, Butler et al 8 have reported somatic mutations in 2/10 of Burkitt's lymphoma cell lines, and in 2/64 of primary NHL of B cell lineage. However, cytogenetic analyses carried out in a subgroup of NHLs revealed 10q22-25 abnormalities in the absence of mutations or deletions of PTEN. In our work, results obtained with PTEN should be considered with caution since only D10S541 (an external marker) was informative in our samples ( Figure  1d ). We detected one case of genetic instability in a peripheral T cell (L-369) and a diffuse large cell lymphoma (lymphoblastic) (L-272), and two cases of LOH in B-NHLs (L-91, follicular, and L-421, diffuse large cell lymphoma-anaplastic large cell). However, the coexistence of LOH and a translocation t(14; 18) in the centrocytic L-91 tumor (data not shown) is in accordance with a cooperative effect between these two abnormalities during the malignant transformation of NHLs, previously suggested by Siebert et al. 4 In spite of the reduced size of this sample, our results suggest that alterations of the apoptotic signalling pathway involving p73 and PTEN might be considered as an important event in the development of a fraction of NHLs. However, further studies are needed to assess this hypothesis. 1 1 with Ph-positive ALL, 1 while it is not indicated in patients with standard-risk ALL in first remission. For optimal treatment planning it is necessary to discriminate between Ph-positive and Ph-negative ALL as early as possible.
Laboratorio de Genética Molecular Humana
Micromegakaryocytes are frequently found in myelodysplastic syndrome (MDS), in acute nonlymphoid leukemia, especially acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS), and in chronic myelogeneous leukemia (CML) in chronic phase or blastic phase. [2] [3] [4] [5] There are, however, only a few reports on the presence of micromegakaryocytes in ALL. The significance of micromegakaryocytes in ALL remained unknown.
Between December 1987 and December 1998, 67 patients with ALL, aged 16-76 years with a median age of 44, were referred to the Hematology Sections of our four hospitals. The diagnosis of ALL was confirmed based on the morphology of blasts, cytochemical studies and flow cytometric analysis according to the FAB criteria (Table 1) . Cytogenetic analysis revealed t(9;22) in 18 (27%) of the 66 patients examined excluding one patient in whom leukemic cell culture failed FAB, French-American-British classification system; mMgk/Mgk, micromegakaryocytes/total megakaryocytes counted; Dry, dry tap; nl, normal karyotype, 46XY or 46XX; MAKA, major karyotypic abnormalities; neg, negative; pos, positive. a Dry tap or counted megakaryocytes were less than 10.
Figure 1
May-Grunwald-Giemsa stained preparation of bone marrow showing a micromegakaryocyte with a round nucleus and cytoplasm of mature staining properties with a granular structure.
to provide cells in metaphase good enough to analyze. Including the use of bone marrow cells obtained at the time of diagnosis and cryopreserved at −196°C after informed consent was obtained, PCR for the minor bcr/abl transcript was performed in 39 patients and was positive in 19 patients (49%), and PCR for the major bcr/abl transcript was positive in nine (26%) of 35 patients. FISH analysis with the use of the Vysis LSI bcr/abl translocation probe (Vysis, Downers Grove, IL, USA) and according to the specific instructions provided by the manufacturer showed that 14 patients (67%) had either minor or major or both bcr/abl fusion gene among 21 patients. The rate of detection of bcr/abl fusion gene varied depending on the methods employed. This did not, however, result from differences in sensitivity or specificity of each method to identify the bcr/abl fusion gene, because RT-PCR or FISH could not be performed in all patients as they were not included in our routine examinations at presentation of patients with acute leukemia and were often conducted to confirm the results of cytogenetic analysis. It is well known that cytogenetic analysis is not sufficient to identify Ph-positive ALL in the case of masked and variant Ph. 6 We defined ALL as Ph-positive ALL when t(9;22) or bcr/abl fusion gene was identified by any method of cytogenetic analysis, RT-PCR or FISH. We could not obtain any information on the presence or absence of Ph in one patient.
Bone marrow smears from each patient that had been stained with May-Grü nwald-Giemsa at the time of diagnosis, were retrospectively reviewed to identify micromegakaryocytes, while blinded to patients' name and/or to the results of analysis of Ph. Micromegakaryocytes were defined as megakaryocytes with one or two small round and chromatin dense nuclei, cytoplasm of mature staining properties and a granular structure, being less than 25 m in diameter according to the average cell size of micromegakaryocytes in two previous studies 3, 4 (Figure 1 ). Micromegakaryocytes were identified among 25 megakaryoctytes found in one to four bone marrow smears made simultaneously at diagnosis. Micromegakaryocytes were found in 21 (38%) out of 56 evaluable patients with the incidence of 1/25 megakaryocytes to 17/25 (median 2/25), excluding 11 patients in whom bone marrow aspiration resulted in failure with dry tap or only less than 10 megakaryocytes could be counted. Of these 56 patients, 55 could be evaluated for the presence of Philadelphia chromosome or bcr/abl fusion gene. Micromegakaryocytes were found in 16 (76%) of 21 patients with Phpositive ALL, compared with five (15%) among the 34 patients with Ph-negative ALL (P Ͻ 0.0001, the chi-square test).
The origin of both minor and major bcr/abl-positive ALL is suggested to be heterogeneous with involvement of either a pluripotent precursor or lymphoid lineage-commited hemopoietic progenitor cell by studies of lineage derivation of Ph-positive ALL. 7 Ph-positive ALL cells are shown to express receptors to granulocyte colony-stimulating Leukemia factor and granulocyte-macrophage colony-stimulating factor (GM-CSF), to produce GM-CSF and to proliferate in response to this cytokine. 8 In this study, micromegakaryocytes were identified dysequally in Ph-positive ALL compared with Ph-negative ALL. Micromegakaryocytes have been reported to be found in MDS, in CML, and in AML, especially AML/TMDS. These findings may imply that micromegakaryocyte is a morphological marker of involvement of multipotent stem cells in clonal hemopathies.
In conclusion, micromegakaryocytes in the marrow smears of patients with ALL were closely associated with the bcr/abl fusion gene. Molecular analysis and/or cytogenetic analysis should be performed to confirm whether ALL is Ph positive or negative. However, it is easy and quick to examine bone marrow smears for the presence of micromegakaryocytes which leads to suspecting ALL strongly of being Ph positive.
